Thrombosis Clinical Trial
Official title:
Mesoglycan for Pain Control After Open Excisional HAEMOrrhoidectomy (MeHAEMO): An Observational Multicentre Study on Behalf of the Italian Society of Colorectal Surgery (SICCR)
Haemorrhoidal disease (HD) is the most common proctological disease, with a prevalence that
can reach up to 39% of the population. Although I and II degree HD can be treated
successfully with medical therapy or office-based procedures , excisional haemorrhoidectomy
remains the gold standard technique in patients with III and IV degree HD, obtaining a much
lower rate of recurrence than non-excisional methods, such as Doppler-guided haemorrhoidal
artery ligation or stapled haemorrhoidopexy. However, both open and closed
haemorrhoidectomies are associated with a significant rate of post-operative pain , which may
be due to the incorporation of sensitive anal mucosa and fibres of the internal sphincters
during the ligation of the vascular pedicle, post-operative scars, hygiene/social habits,
hard stool, or oedema of the necessary mucocutaneous bridge.
Regarding the oedema/thrombosis of the mucocutaneous bridges, we strongly believe that it is
the main cause of post-operative pain, and we have shown that the use of mesoglycan, a
polysaccharide complex with antithrombotic and profibrinolytic properties, can reduce the
rate of post-operative thrombosis and consequently post-operative pain 7-10 days after the
procedures, improving patient quality of life and speeding up the recovery of daily
activities.
Furthermore, its usefulness is also evident in the treatment of the acute phase of external
haemorrhoidal thrombosis.
The aim of the study was to evaluate the efficacy of mesoglycan in the post-operative period
of patients who underwent open excisional diathermy haemorrhoidectomy, confirming the
previously obtained results
This was a retrospective multicentre study and is reported according to the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) statement for cohort studies
Between September and December 2017, 206 patients with III and IV degree HD, according to
Goligher classification, from sixteen colorectal referral centres belonging to SICCR (Società
Italiana di Chirurgia Colorettale), who satisfied inclusion criteria underwent open excision
haemorrhoidectomy.
The results obtained were compared with a homogeneous sample of 192 patients who underwent
OEH in the same centres between April and July 2017 and who had received standard
post-operative therapy without mesoglycan.
All patients received the standard post-operative therapy (a recommended oral dose of
ketorolac tromethamine of 10 mg every 4-6 hours, not exceeding 40 mg per day and not
exceeding 5 post-operative days according to the indications for short-term management of
moderate/severe acute post-operative pain and stool softeners) plus mesoglycan (Prisma® 30 mg
2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet
twice/day for an additional 30 days, Mediolanum Farmaceutici, Milan, Italy).
In each referral centre, the procedures were carried out by an experienced surgeon who had
performed more than 200 haemorrhoidectomies.
A clinical external examination was performed the first post-operative day, and an anorectal
digital evaluation with proctoscopy was performed at T2, T3 and T4.
During each follow-up visit, post-operative pain was evaluated at rest, after defecation and
after anorectal digital examination using a visual analogue scale (minimum score = 0; maximum
score = 10).
Quality of life was evaluated pre- and post-operatively 90 days after the procedure using the
SF-12 questionnaire.
Polypharmacy was defined as 5 or more medications daily. Thrombosis was defined as one or
more swollen painful piles at the site of the mucocutaneous bridge and was assessed at T2, T3
and T4.
Surgical wound healing (granulation) was evaluated at T2, T3 and T4 using the following 3
items: infected, granulating, healed.
Autonomy was evaluated at T2, T3 and T4 using the following 4 items: complete inactivity,
total autonomy at home, ability to drive, return to normal activities (autonomy at home,
driving, working).
Bowel movements were evaluated, according to the proper guidelines, at T2, T3 and T4, and
patients were classified in three categories: regular, constipation or diarrhoea.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT05426564 -
Exploratory Assessment of the Quantra® System in Adult ECMO Patients
|
||
Not yet recruiting |
NCT05830916 -
Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
|
||
Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
Completed |
NCT02526628 -
Thrombosis and Neurocognition in Klinefelter Syndrome
|
||
Completed |
NCT02439190 -
CV004-007 Thrombosis Chamber Study
|
Phase 1 | |
Completed |
NCT02341638 -
Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01855516 -
Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin
|
N/A | |
Unknown status |
NCT00983112 -
Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery
|
Phase 4 | |
Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
Completed |
NCT00346424 -
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
|
Phase 3 | |
Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
Terminated |
NCT00303420 -
Alteplase for Blood Flow Restoration in Hemodialysis Catheters
|
Phase 4 | |
Completed |
NCT00143715 -
Oral Vitamin K for Warfarin Associated Coagulopathy
|
Phase 3 | |
Completed |
NCT00039858 -
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
|
Phase 4 | |
Completed |
NCT00007410 -
Genetic Architecture of Plasma T-PA and PAI-1
|
N/A | |
Completed |
NCT00000538 -
Dietary Effects on Lipoproteins and Thrombogenic Activity
|
Phase 3 | |
Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A |